candesartan has been researched along with Auricular Fibrillation in 36 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to evaluate whether treatment with candesartan on top of conventional treatment could prevent new onset AF in patients with aortic valve stenosis (AS) after aortic valve replacement." | 9.17 | Prevention of atrial fibrillation in patients with aortic valve stenosis with candesartan treatment after aortic valve replacement. ( Andersen, LI; Dahl, JS; Haghfelt, T; Møller, JE; Pellikka, PA; Poulsen, MK; Veien, K; Videbæk, L, 2013) |
| "We investigated the efficacy of carvedilol for preventing the recurrence of atrial fibrillation and reducing QT prolongation induced by bepridil." | 9.17 | Carvedilol is effective and safe in combination with bepridil for persistent atrial fibrillation and decreases the QT prolongation induced by bepridil therapy. ( Kawamura, M; Kobayashi, Y; Munetsugu, Y; Tanno, K, 2013) |
| "This study has evaluated whether candesartans prevent the recurrence of atrial fibrillation (AF) and decrease type III procollagen-N-peptide (PIIINP) levels." | 9.14 | Candesartan decreases type III procollagen-N-peptide levels and inflammatory marker levels and maintains sinus rhythm in patients with atrial fibrillation. ( Asano, T; Ito, H; Kawamura, M; Kobayashi, Y; Miyoshi, F; Onuki, T; Tanno, K; Watanabe, N, 2010) |
| "It was our aim to study the levels of L-arginine, the substrate for nitric oxide and asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, and their relation to the maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation (AF), as well as the effects of angiotensin receptor blockade on these variables." | 9.14 | L-arginine, asymmetric dimethylarginine and rhythm outcome after electrical cardioversion for atrial fibrillation. ( Arnesen, H; Bratseth, V; Seljeflot, I; Smith, P; Tveit, A, 2010) |
| "We investigated 171 patients with persistent AF who underwent electrical cardioversion in a prospective, blinded, placebo-controlled clinical trial (Candesartan in the Prevention of Relapsing Atrial Fibrillation, CAPRAF)." | 9.14 | Candesartan, NT-proBNP and recurrence of atrial fibrillation after electrical cardioversion. ( Abdelnoor, M; Arnesen, H; Grundvold, I; Seljeflot, I; Smith, P; Tveit, A, 2009) |
| "We assessed the risk of adverse cardiovascular (CV) outcomes associated with atrial fibrillation (AF) in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program, which enrolled patients with chronic heart failure (CHF) and a broad range of ejection fractions (EFs)." | 9.12 | Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. ( Ducharme, A; Granger, CB; McMurray, JJ; Michelson, EL; Olsson, LG; Pfeffer, MA; Puu, M; Swedberg, K; Yusuf, S, 2006) |
| "Inflammatory markers, their relation to maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation (AF), and the effect of candesartan were investigated in a double-blind placebo-controlled study (CAPRAF)." | 9.12 | Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. ( Abdelnoor, M; Arnesen, H; Grundvold, I; Seljeflot, I; Smith, P; Tveit, A, 2007) |
| "Rabbits subjected to ventricular tachypacing at 380 to 400 bpm for 4 weeks in the absence and presence of treatment with pioglitazone, candesartan, and combined pioglitazone and candesartan were assessed by electrophysiologic study, atrial fibrosis measurements, and cytokine expression analyses." | 7.74 | Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. ( Harata, S; Inden, Y; Kitamura, K; Murohara, T; Nattel, S; Shimano, M; Tsuji, Y; Uchikawa, T, 2008) |
| "Candesartan effects were only observed if the baseline fibrillatory rate was high [>420 fpm: 445 +/- 21 vs." | 6.73 | Fibrillatory rate response to candesartan in persistent atrial fibrillation. ( Bollmann, A; Husser, D; Olsson, SB; Smith, P; Sörnmo, L; Stridh, M; Tveit, A, 2008) |
| "We hypothesised that high-sensitivity troponin I (hs-TnI) might predict long-term rhythm outcome after cardioversion for persistent atrial fibrillation (AF), and that maintenance of sinus rhythm and/or treatment with the angiotensin II type 1 receptor blocker candesartan would reduce hs-TnI levels." | 5.22 | High-Sensitivity Troponin I and Rhythm Outcome after Electrical Cardioversion for Persistent Atrial Fibrillation. ( Arnesen, H; Horjen, AW; Norseth, J; Seljeflot, I; Smith, P; Tveit, A; Ulimoen, SR, 2016) |
| " The aim of this study was to evaluate whether treatment with candesartan on top of conventional treatment could prevent new onset AF in patients with aortic valve stenosis (AS) after aortic valve replacement." | 5.17 | Prevention of atrial fibrillation in patients with aortic valve stenosis with candesartan treatment after aortic valve replacement. ( Andersen, LI; Dahl, JS; Haghfelt, T; Møller, JE; Pellikka, PA; Poulsen, MK; Veien, K; Videbæk, L, 2013) |
| "We investigated the efficacy of carvedilol for preventing the recurrence of atrial fibrillation and reducing QT prolongation induced by bepridil." | 5.17 | Carvedilol is effective and safe in combination with bepridil for persistent atrial fibrillation and decreases the QT prolongation induced by bepridil therapy. ( Kawamura, M; Kobayashi, Y; Munetsugu, Y; Tanno, K, 2013) |
| "The Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM II study) is an open-label randomized comparison between an ARB (candesartan) and a CCB (amlodipine) in the treatment of paroxysmal AF associated with hypertension." | 5.15 | Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). ( Aizawa, Y; Atarashi, H; Fukatani, M; Hirai, M; Hirayama, A; Inoue, H; Kamakura, S; Kato, T; Kodama, I; Koretsune, Y; Kumagai, K; Kurachi, Y; Mitamura, H; Nakaya, H; Ogawa, S; Ohe, T; Ohtsu, H; Okumura, K; Saikawa, T; Sakurai, M; Sato, T; Sugi, K; Watanabe, E; Yamashita, T; Yamazaki, T, 2011) |
| "To evaluate the effects of the angiotensin II type 1 receptor blocker candesartan on P-wave signal-averaged electrocardiogram (P-SAECG) after electrical cardioversion in patients with atrial fibrillation (AF)." | 5.14 | Effects of angiotensin receptor blockade on serial P-wave signal-averaged electrocardiograms after electrical cardioversion of persistent atrial fibrillation. ( Arnesen, H; Grundvold, I; Hegbom, F; Smith, P; Tveit, A, 2009) |
| "This study has evaluated whether candesartans prevent the recurrence of atrial fibrillation (AF) and decrease type III procollagen-N-peptide (PIIINP) levels." | 5.14 | Candesartan decreases type III procollagen-N-peptide levels and inflammatory marker levels and maintains sinus rhythm in patients with atrial fibrillation. ( Asano, T; Ito, H; Kawamura, M; Kobayashi, Y; Miyoshi, F; Onuki, T; Tanno, K; Watanabe, N, 2010) |
| "It was our aim to study the levels of L-arginine, the substrate for nitric oxide and asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, and their relation to the maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation (AF), as well as the effects of angiotensin receptor blockade on these variables." | 5.14 | L-arginine, asymmetric dimethylarginine and rhythm outcome after electrical cardioversion for atrial fibrillation. ( Arnesen, H; Bratseth, V; Seljeflot, I; Smith, P; Tveit, A, 2010) |
| "We investigated 171 patients with persistent AF who underwent electrical cardioversion in a prospective, blinded, placebo-controlled clinical trial (Candesartan in the Prevention of Relapsing Atrial Fibrillation, CAPRAF)." | 5.14 | Candesartan, NT-proBNP and recurrence of atrial fibrillation after electrical cardioversion. ( Abdelnoor, M; Arnesen, H; Grundvold, I; Seljeflot, I; Smith, P; Tveit, A, 2009) |
| "Transthoracic echocardiographic examination was performed within 4 h after cardioversion for all the patients in the CAPRAF (Candesartan in the Prevention of Relapsing Atrial Fibrillation) study." | 5.13 | The predictive value of transthoracic echocardiographic variables for sinus rhythm maintenance after electrical cardioversion of atrial fibrillation. Results from the CAPRAF study, a prospective, randomized, placebo-controlled study. ( Abdelnoor, M; Arnesen, H; Grundvold, I; Seljeflot, I; Smith, P; Tveit, A, 2008) |
| "We assessed the risk of adverse cardiovascular (CV) outcomes associated with atrial fibrillation (AF) in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program, which enrolled patients with chronic heart failure (CHF) and a broad range of ejection fractions (EFs)." | 5.12 | Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. ( Ducharme, A; Granger, CB; McMurray, JJ; Michelson, EL; Olsson, LG; Pfeffer, MA; Puu, M; Swedberg, K; Yusuf, S, 2006) |
| "The Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM II study) is a randomized comparative evaluation of an angiotensin II type 1 blocker (candesartan) and a dihydropiridine calcium blocker (amlodipine), both combined with antithrombotic therapy, as an antiarrhythmic therapy for the treatment of paroxysmal AF (PAF) associated with hypertension." | 5.12 | Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension. ( Aizawa, Y; Atarashi, H; Fukatani, M; Hirai, M; Hirayama, A; Inoue, H; Kamakura, S; Kato, T; Kodama, I; Koretsune, Y; Kumagai, K; Kurachi, Y; Mitamura, H; Nakaya, H; Ogawa, S; Ohe, T; Ohtsu, H; Okumura, K; Saikawa, T; Sakurai, M; Sugi, K; Watanabe, E; Yamashita, T; Yamazaki, T, 2006) |
| "Inflammatory markers, their relation to maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation (AF), and the effect of candesartan were investigated in a double-blind placebo-controlled study (CAPRAF)." | 5.12 | Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. ( Abdelnoor, M; Arnesen, H; Grundvold, I; Seljeflot, I; Smith, P; Tveit, A, 2007) |
| "Rabbits subjected to ventricular tachypacing at 380 to 400 bpm for 4 weeks in the absence and presence of treatment with pioglitazone, candesartan, and combined pioglitazone and candesartan were assessed by electrophysiologic study, atrial fibrosis measurements, and cytokine expression analyses." | 3.74 | Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. ( Harata, S; Inden, Y; Kitamura, K; Murohara, T; Nattel, S; Shimano, M; Tsuji, Y; Uchikawa, T, 2008) |
| "Treatment with candesartan had no influence on serum YKL-40 levels." | 2.78 | Angiotensin II blockade, YKL-40 and maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. ( Arnesen, H; Seljeflot, I; Smith, P; Svendsen, JH; Tveit, A, 2013) |
| "Candesartan effects were only observed if the baseline fibrillatory rate was high [>420 fpm: 445 +/- 21 vs." | 2.73 | Fibrillatory rate response to candesartan in persistent atrial fibrillation. ( Bollmann, A; Husser, D; Olsson, SB; Smith, P; Sörnmo, L; Stridh, M; Tveit, A, 2008) |
| "Candesartan has no additional effect on the rates of postoperative AF when added to ACEI." | 2.73 | Effect of renin-angiotensin aldosteron system blockers on postoperative atrial fibrillation. ( Dede, O; Duver, H; Ibrisim, E; Kapan, S; Ozaydin, M; Peker, O; Turker, Y; Varol, E, 2008) |
| "Candesartan was administered orally (10 mg/kg/day) for one week before rapid pacing and was continued for five weeks." | 1.32 | Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. ( Arakawa, K; Gondo, N; Kumagai, K; Nakashima, H; Saku, K; Urata, H, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (61.11) | 29.6817 |
| 2010's | 14 (38.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horjen, AW | 2 |
| Ulimoen, SR | 2 |
| Norseth, J | 2 |
| Svendsen, JH | 2 |
| Smith, P | 11 |
| Arnesen, H | 10 |
| Seljeflot, I | 9 |
| Tveit, A | 11 |
| Abdul-Rahim, AH | 1 |
| Perez, AC | 1 |
| Fulton, RL | 1 |
| Jhund, PS | 1 |
| Latini, R | 1 |
| Tognoni, G | 1 |
| Wikstrand, J | 1 |
| Kjekshus, J | 1 |
| Lip, GY | 2 |
| Maggioni, AP | 3 |
| Tavazzi, L | 1 |
| Lees, KR | 1 |
| McMurray, JJ | 4 |
| Bollmann, A | 2 |
| Husser, D | 2 |
| Stridh, M | 2 |
| Sörnmo, L | 2 |
| Olsson, SB | 2 |
| Mariscalco, G | 1 |
| Dominici, C | 1 |
| Banach, M | 1 |
| Sala, A | 1 |
| Ozaydin, M | 2 |
| Peker, O | 2 |
| Hegbom, F | 1 |
| Grundvold, I | 5 |
| Akhmedov, VA | 1 |
| Dolgikh, VT | 1 |
| Naumov, DV | 1 |
| Dvornikov, VE | 1 |
| Kumagai, K | 5 |
| Kawamura, M | 2 |
| Ito, H | 1 |
| Onuki, T | 1 |
| Miyoshi, F | 1 |
| Watanabe, N | 1 |
| Asano, T | 1 |
| Tanno, K | 2 |
| Kobayashi, Y | 2 |
| Hall, MC | 1 |
| Kirubakaran, S | 1 |
| Choudhury, R | 1 |
| Abidin, N | 1 |
| Peters, NS | 1 |
| Garratt, CJ | 1 |
| Bratseth, V | 1 |
| Yamashita, T | 2 |
| Inoue, H | 2 |
| Okumura, K | 2 |
| Kodama, I | 2 |
| Aizawa, Y | 2 |
| Atarashi, H | 2 |
| Ohe, T | 2 |
| Ohtsu, H | 2 |
| Kato, T | 2 |
| Kamakura, S | 2 |
| Kurachi, Y | 2 |
| Koretsune, Y | 2 |
| Saikawa, T | 2 |
| Sakurai, M | 2 |
| Sato, T | 1 |
| Sugi, K | 2 |
| Nakaya, H | 2 |
| Hirai, M | 2 |
| Hirayama, A | 2 |
| Fukatani, M | 2 |
| Mitamura, H | 2 |
| Yamazaki, T | 2 |
| Watanabe, E | 2 |
| Ogawa, S | 2 |
| Goette, A | 2 |
| Dahl, JS | 1 |
| Videbæk, L | 1 |
| Poulsen, MK | 1 |
| Pellikka, PA | 1 |
| Veien, K | 1 |
| Andersen, LI | 1 |
| Haghfelt, T | 1 |
| Møller, JE | 1 |
| Munetsugu, Y | 1 |
| Klein, HU | 1 |
| Nakashima, H | 2 |
| Urata, H | 2 |
| Gondo, N | 2 |
| Arakawa, K | 2 |
| Saku, K | 1 |
| Ducharme, A | 3 |
| Swedberg, K | 4 |
| Pfeffer, MA | 3 |
| Cohen-Solal, A | 2 |
| Granger, CB | 3 |
| Michelson, EL | 3 |
| Olsson, L | 2 |
| Rouleau, JL | 2 |
| Young, JB | 2 |
| Yusuf, S | 3 |
| Olsson, LG | 1 |
| Puu, M | 2 |
| Olofsson, B | 1 |
| Olufsen, M | 1 |
| Abdelnoor, M | 4 |
| Watson, T | 1 |
| Kakar, P | 1 |
| Celik, T | 1 |
| Iyisoy, A | 1 |
| Dede, O | 1 |
| Varol, E | 1 |
| Kapan, S | 1 |
| Turker, Y | 1 |
| Duver, H | 1 |
| Ibrisim, E | 1 |
| Chrysostomakis, SI | 1 |
| Karalis, IK | 1 |
| Simantirakis, EN | 1 |
| Koutsopoulos, AV | 1 |
| Mavrakis, HE | 1 |
| Chlouverakis, GI | 1 |
| Vardas, PE | 1 |
| Shimano, M | 1 |
| Tsuji, Y | 1 |
| Inden, Y | 1 |
| Kitamura, K | 1 |
| Uchikawa, T | 1 |
| Harata, S | 1 |
| Nattel, S | 1 |
| Murohara, T | 1 |
| Wilson, LD | 1 |
| Tsai, CT | 1 |
| Ideishi, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Portable Measurement Methods Combined With Artificial Intelligence in Detection of Atrial Fibrillation[NCT04917653] | 100 participants (Anticipated) | Observational | 2021-06-07 | Recruiting | |||
| Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial[NCT04696120] | Phase 2 | 200 participants (Anticipated) | Interventional | 2021-03-02 | Not yet recruiting | ||
| Confirm Rx Insertable Cardiac Monitor for Primary Atrial Fibrillation Detection in High Risk Heart Failure Patients[NCT04818645] | 477 participants (Anticipated) | Interventional | 2023-01-31 | Recruiting | |||
| [NCT00130975] | Phase 3 | 200 participants | Interventional | 2001-04-30 | Completed | ||
| Colchicine for the Prevention of Atrial Fibrillation Recurrence After Electrical Cardioversion of Persistent Atrial Fibrillation.[NCT02582190] | Phase 3 | 0 participants (Actual) | Interventional | 2017-12-02 | Withdrawn (stopped due to Investigational Medicinal Product Supplies) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for candesartan and Auricular Fibrillation
| Article | Year |
|---|---|
Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart
Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; Biomarkers; Biphenyl Compounds; | 2015 |
[Upstream approach for atrial fibrillation].
Topics: Amiodarone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I | 2010 |
17 trials available for candesartan and Auricular Fibrillation
| Article | Year |
|---|---|
High-sensitivity troponin I in persistent atrial fibrillation - relation to NT-proBNP and markers of inflammation and haemostasis.
Topics: Aged; Antihypertensive Agents; Atrial Fibrillation; Benzimidazoles; Biomarkers; Biphenyl Compounds; | 2018 |
Angiotensin II blockade, YKL-40 and maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation.
Topics: Adipokines; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Atrial Fibrillation; Atrial R | 2013 |
High-Sensitivity Troponin I and Rhythm Outcome after Electrical Cardioversion for Persistent Atrial Fibrillation.
Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Biphenyl | 2016 |
Fibrillatory rate response to candesartan in persistent atrial fibrillation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Biphenyl Compoun | 2008 |
Effects of angiotensin receptor blockade on serial P-wave signal-averaged electrocardiograms after electrical cardioversion of persistent atrial fibrillation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Biphenyl Compoun | 2009 |
Candesartan decreases type III procollagen-N-peptide levels and inflammatory marker levels and maintains sinus rhythm in patients with atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzimidazoles; Bepridil; Biomarkers; Biphenyl Co | 2010 |
L-arginine, asymmetric dimethylarginine and rhythm outcome after electrical cardioversion for atrial fibrillation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Arginine; Atrial Fibrillation; Benzimidazoles; Biphen | 2010 |
Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Biph | 2011 |
Prevention of atrial fibrillation in patients with aortic valve stenosis with candesartan treatment after aortic valve replacement.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Aortic Valve Stenosis; Atrial Fibr | 2013 |
Carvedilol is effective and safe in combination with bepridil for persistent atrial fibrillation and decreases the QT prolongation induced by bepridil therapy.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzimidazoles; Bepridil; Biphenyl Compounds; Car | 2013 |
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Biphenyl Compoun | 2006 |
Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Biphenyl C | 2006 |
Candesartan in the prevention of relapsing atrial fibrillation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Biphenyl Compoun | 2007 |
Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Biomarkers; Biph | 2007 |
Effect of renin-angiotensin aldosteron system blockers on postoperative atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzy | 2008 |
Candesartan, NT-proBNP and recurrence of atrial fibrillation after electrical cardioversion.
Topics: Aged; Atrial Fibrillation; Benzimidazoles; Biomarkers; Biphenyl Compounds; Double-Blind Method; Elec | 2009 |
The predictive value of transthoracic echocardiographic variables for sinus rhythm maintenance after electrical cardioversion of atrial fibrillation. Results from the CAPRAF study, a prospective, randomized, placebo-controlled study.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzim | 2008 |
17 other studies available for candesartan and Auricular Fibrillation
| Article | Year |
|---|---|
Angiotensin converting-enzyme inhibitors and candesartan have no effects on atrial fibrillation after cardiac surgery: comment on: Mehmet Ozaydin et al. "Effect of renin-angiotensin aldosterone system blockers on postoperative atrial fibrillation".
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillati | 2010 |
Angiotensin converting-enzyme inhibitors and candesartan have no effects on atrial fibrillation after cardiac surgery: Reply.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillati | 2010 |
Relation between atrial fibrillatory rate and markers of inflammation and haemostasis in persistent human atrial fibrillation.
Topics: Antihypertensive Agents; Atrial Fibrillation; Benzimidazoles; Biomarkers; Biphenyl Compounds; Electr | 2009 |
[Preventive strategy for atrial fibrillation in arterial hypertension].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia A | 2009 |
Effects of angiotensin receptor blockade on atrial electrical remodelling and the 'second factor' in a goat burst-paced model of atrial fibrillation.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atrial Fibrillation; Benzimidazoles; Biph | 2010 |
The vanishing story of angiotensin II receptor blockers in the treatment of atrial fibrillation.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Biphenyl C | 2011 |
Blockade of atrial angiotensin II type 1 receptors: a novel antiarrhythmic strategy to prevent atrial fibrillation?
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Atrial Fibrillation; Benzimidazo | 2003 |
Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Atrial Fibrillation; Benzimidazo | 2003 |
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Biphenyl Compoun | 2006 |
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Biphenyl Compoun | 2006 |
Heart failure management. Interview with Karl Swedberg.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2007 |
Cardioversion for atrial fibrillation: does inflammation matter?
Topics: Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Biphenyl Compounds; C- | 2007 |
Angiotensin receptor blockers in the prevention of atrial fibrillation recurrence: need for a definitive trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Biphenyl Compoun | 2008 |
Angiotensin II type 1 receptor inhibition is associated with reduced tachyarrhythmia-induced ventricular interstitial fibrosis in a goat atrial fibrillation model.
Topics: Animals; Atrial Fibrillation; Benzimidazoles; Biphenyl Compounds; Cardiac Pacing, Artificial; Diseas | 2007 |
Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Benzimi | 2008 |
Heart failure-related atrial fibrillation: a new model for a new prevention strategy?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Benzimidazoles; Biphenyl Comp | 2008 |
Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; An | 2000 |